PULMONARY

PULMONARY

AN ADVANCED CUSTOMISABLE COMPREHENSIVE DPI CAPSULE PORTFOLIO OFFERING

Frédérique Bordes-Picard and Julien Lamps discuss the factors driving development in the area of capsule-based dry powder inhalers, and how the company’s Capsugel^® Zephyr™ portfolio offering is perfectly positioned to meet and exceed industry’s growing and evolving requirements.

PULMONARY

PULMOCRAFT™: ENGINEERING SPRAY-DRIED POWDERS FOR PULMONARY DELIVERY

Richard Johnson discusses the techniques of jet milling and spray drying for the production of formulations for dry powder inhalers, and introduces Upperton Pharma’s PulmoCraft™ technology, which combines the advantages of both.

CONNECTIVITY

Mauro Citterio

Berry Global Healthcare

RS01X – BERRY GLOBAL HEALTHCARE’S SINGLE-DOSE DPI GOES DIGITAL WITH AMIKO’S RESPIRO

Mauro Citterio, Director, Marco Franza and Martijn Grinovero discuss Berry and Amiko’s partnership to develop the RS01X connected single-dose dry powder inhaler, based on Berry’s commercialised RS01 inhaler and Amiko’s Respiro digital health platform.

CONNECTIVITY

Edgar Hernan Cuevas Brun

HCmed Innovations

IMPROVING INHALATION THERAPY ADHERENCE WITH CONNECTED DEVICES

Edgar Hernan Cuevas Brun discusses the role of connectivity in improving adherence to medication and introduces the company’s mesh nebuliser smart cap, Pulmogine+.

RESPIRATORY

Josef Schmid

Gerresheimer

DEVELOPMENT & PRODUCTION OF RESPIMAT^® REUSABLE INHALER HOUSING MODULE

Josef Schmid, Markus Müller and Nina Zielonka discuss Gerresheimer’s recent work on developing the housing module for Boehringer Ingelheim’s new version of the Respimat inhaler.

PULMONARY

Edgar Hernan Cuevas Brun

HCmed Innovations

AN INTRODUCTION TO SMART BREATH-ACTUATED NEBULISERS

Edgar Hernan Cuevas Brun considers the benefits of smart breath-actuated nebulisers and looks at the latest technology contributing to the evolution of nebulisers.

INDUSTRIALISATION

Bert Dekens

Hosokawa Micron

ONE-STOP SHOP FOR TOTAL MIXING SOLUTIONS FOR PHARMACEUTICAL MANUFACTURERS

Bert Dekens discusses Hosokawa Micron's offering for pharmaceutical powder mixing, including the Cyclomix high-shear mixer and the Nauta low-shear mixer, and how the company’s technology solutions take a broader approach to the full mixing process than simply providing a mixing machine.

PULMONARY

João Pereira

Hovione

SEMI-AUTOMATION IN INHALER TESTING – EXPLORING THE POTENTIAL AND PRACTICALITIES

João Pereira, Raquel Borda D’Água, Mark Copley and Anna Sipitanou, discuss the semi-automation of cascade impactor testing and the benefits it can bring in terms of quality of orally inhaled product test data, and reductions in cost and effort associated with routine, critical measurements.

RESPIRATORY

Steve Haswell

Kindeva Drug Delivery

COLD FILLING VERSUS PRESSURE FILLING: THE CASE FOR VERSATILE, FULLY INTEGRATED CDMOs

Steve Haswell compares the two main processes for manufacturing pressurised metered dose inhalers – and examines the value for pharmaceutical companies of working with contract development and manufacturing organisations that have expertise in both processes.

PULMONARY

Dr Sion Coulman

Cardiff University

EVALUATING THE MECHANICAL PROPERTIES OF “EXTRA DRY” HARD-SHELL CAPSULES

Sion Coulman, Siamac Parker, Prof James Birchall, Susana Ecenarro and Mahmoud Farag discuss new developments in low moisture content capsule technology for hygroscopic and very moisture-labile APIs.

RESPIRATORY

Howard Burnett

Aptar Pharma

HOW EMOTIONAL INTELLIGENCE IS DRIVING IMPROVEMENTS & MEETING CHALLENGES IN PULMONARY DELIVERY

Howard Burnett explores how emotional intelligence can foster partnerships that have the potential to drive advances in understanding and improving patient outcomes, and presents the case for a single-source, turnkey approach to pulmonary solution development.

PULMONARY

MG2

MG2 AUTOMATION SOLUTIONS FOR INHALATION: R&D, TECHNOLOGICAL PARTNERSHIPS & SUCCESSFUL CASE HISTORIES

Italian automation solutions provider MG2 describes its offering in the inhalation space, including unique benefits of collaboration and two example partnerships.

COVID-19 NEWS

AEROGEN JOINS FORCES WITH 15 COMPANIES FOR COVID-19 INHALED THERAPIES

Aerogen has revealed details of a broad collaborative effort with more than 15 pharmaceutical companies for the development of covid-19 vaccines and treatments, including one with Synairgen for Solo/Ultra nebuliser-delivered SNG001 (inhaled interferon-beta-1a).

SUSTAINABILITY

Wim Kehoe

H&T Presspart

CUTTING CARBON IMPACT: CREATING A SUSTAINABLE pMDI COMPONENT SUPPLY CHAIN

Wim Kehoe and Ameet Sule discuss H&T Presspart’s approach to sustainability, and the developments that are helping to reduce the carbon footprint of pMDIs.

SUSTAINABILITY

Mike Needham

Kindeva Drug Delivery

NEXT-GENERATION PMDIS: A HOLISTIC, PATIENT-CENTRED APPROACH TO SUSTAINABILITY

Mike Needham, Phil Cocks and Louise Righton discuss how sustainability should be a central theme of future innovation in inhalation drug delivery but must be balanced with the needs of the patient.

INTERVIEW

Aaron Mann

INTERVIEW WITH AARON MANN, CHIEF EXECUTIVE OFFICER, KINDEVA

In this exclusive interview with ONdrugDelivery, Aaron Mann discusses how Kindeva is positioned to move forward as a major CDMO specialising in inhalation and transdermal dosage forms, having been formed from 3M’s drug delivery in May 2020. We also cover the impact of Covid-19, environmental sustainability, and current challenges faced by the pharmaceutical industry.

ROUNDTABLE

Dr Jeremy Drummond

ROUNDTABLE: JEREMY DRUMMOND, MEDPHARM; STEPHEN RODE, LONZA; AND TORKEL GREN, RECIPHARM

In this roundtable discussion, Jeremy Drummond, Stephen Rode and Torkel Gren discuss trends with different drug dosage forms for different routes of administration, the rise of patient centricity including the shift from the blockbuster model to more tailored products.

EXPERT VIEW

Frédérique Bordes-Picard

ADVANCED CAPSULE TECHNOLOGIES: DRY POWDER INHALERS TO TARGET DISEASE

Frédérique Bordes-Picard  and Julien Lamps discuss the value of capsule-based dry powder inhalers in the modern respiratory market, the factors driving development in this area and considerations for matching a capsule to a device and formulation.

COVID-19 NEWS

TFF AND UNION AGREE LICENSING PACT FOR TFF TECHNOLOGY WITH NICLOSAMIDE FOR THE TREATMENT OF COVID-19

UNION therapeutics has acquired an option to a worldwide, exclusive licence to TFF Pharmaceuticals' Thin Film Freezing (TFF) technology, in combination with niclosamide, covering oral and inhalation formulations, potentially for covid-19, as well as other niclosamide-based therapies.

CONNECTIVITY

Marnik Vaes

SABIC

POLYMERIC EMI SHIELDING: PROVIDING A MORE SECURE FUTURE FOR PATIENTS

Marnik Vaes, Leen-Pieter Deurloo and Martin Sas discuss the role of polymeric electromagnetic interference shielding in providing a more secure future for patients in a connected world.

INTERVIEW

Sai Shankar

Aptar Pharma

INTERVIEW WITH SAI SHANKAR, ADAM SHAIN & MARCUS BATES

Sai Shankar, Adam Shain and Marcus Bates discuss the full potential of connectivity, coronavirus as a potential accelerator of adoption, and the place of connected drug delivery systems within Aptar Pharma’s broader offering to industry.

CONNECTIVITY

Neil Williams

Phillips-Medisize

UNLOCKING INSIGHT FOR PATIENT SUPPORT PROGRAMMES

Neil Williams and Andrew Tubb discuss how insights delivered by a cloud-based connected health system help patient support programmes to monitor and improve medication adherence.

VIDEO

Kevin Deane

Phillips-Medisize

Adding value to Drug Delivery with Connectivity

In this video presentation, Kevin Deane looks at how connectivity applied in drug delivery technologies can provide better solutions for patients and for industry and add value for all stakeholders.

EXPERT VIEW

Salvatore Forte

SENSOR ADVANCEMENTS IN DRUG DELIVERY IMPROVE COMPLIANCE

Salvatore Forte discusses various advancements in sensors that are transforming drug delivery systems, making complex devices more automated, easier to use, and improving patient compliance as a result.

EXPERT VIEW

Beth Crandall

EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?

With the compliance deadline for the EU Medical Device Regulation recently delayed by a year due to the novel coronavirus pandemic, Beth Crandall looks at what it means for the medical device industry.

COVID-19 NEWS

Joe Reynolds

Noble

Telemedicine gains acceptance amid the Covid-19 pandemic

Noble highlights how telemedicine is poised to become a mainstream alternative to the traditional in-person methods of care delivery, with the covid-19 pandemic easing barriers to acceptance and introducing patients to the safety and convenience of telehealth technology.

VIDEO

Mr Tim Freeman

Freeman Technology

WEBINAR: WORKING WITH POWDERS

In this on-demand webinar, the first in a series, Tim Freeman, Managing Director, Freeman Technology, introduces the challenges associated with understanding and predicting powder flowability and looks at how quantifying powder behaviour can aid process performance.

COVID-19 NEWS

Pulmonary Delivery Could Make Niclosamide Effective Against COVID-19

A novel inhaled formulation of the approved antihelminthic drug, niclosamide, is under development at the College of Pharmacy at The University of Texas at Austin for COVID-19. The compound was recently confirmed to exhibit antiviral efficacy in SARS-COV-2 infected cells and indeed was more potent compared with chloroquine, lopinavir and remdesivir, the group said. 

RESPIRATORY

Chris Baron

Aptar Pharma

IS NOW THE TIME TO SHAKE UP THE pMDI ENVIRONMENT?

Chris Baron explores how the use of propellants in pressurised metered dose inhalers has evolved – and how alternative propellants could be a catalyst for greater patient adherence.

RESPIRATORY

Dr Nicolas Schwenck

PARI

NEW DRUG-NEBULISER COMBINATION PRODUCTS: CONSIDERATIONS BEYOND PERFORMANCE

Nicolas Schwenck and Michael Hahn summarise the critical success factors for bringing a new vibrating membrane nebuliser for a drug-device combination product to the market. They highlight opportunities and pitfalls – starting from the evaluation phase, through the development phase and finally during commercialisation.

PULMONARY

Dr Philippe Rogueda

Merxin

OFF-THE-SHELF OR CUSTOM-MADE? CHOOSING A DRY POWDER INHALER

Philippe Rogueda discusses the manifold factors that need to be taken into account when choosing a dry powder inhaler – beyond just the target disease, formulation and patient population.

EXPERT VIEW

Brennan Miles

RESPIRATORY DRUG DELIVERY: THEN, NOW AND SOON

Brennan Miles takes a look back at respiratory drug delivery over the last few decades to see what we can learn from the past – and looks ahead to what the future might look like, covering sustainability, device regulation, and formulation milestones.

EXPERT VIEW

Dr Igor Gonda

PUBLIC INTEREST & INCENTIVES FOR INNOVATORS OF INHALED PRODUCTS

Igor Gonda, David Cipolla and Philippe Rogueda discuss the changes needed to increase the number of approved generic orally inhaled drug products (OIDPs) whilst providing additional incentives to innovators to meet the needs of the general public.

RESPIRATORY

Mark Stansfield

Otitopic

ADVANCING ASPRIHALE^® TO PIVOTAL PK/PD STUDY

Mark Stansfield and Kambiz Yadidi discuss results of their pilot Phase I clinical study of dry-powder inhalation of aspirin.

RESPIRATORY

Bert Dekens

Hosokawa Micron

HOSOKAWA EXTENDS BLENDER RANGE FOR DPI FORMULATIONS

Bert Dekens announces the extension of the the company’s established Cyclomix modular blending technology range, to include small (R&D) scale, mid-range and large-scale systems.

EXPERT VIEW

Phil Seeney

THE OPTIONS FOR CREATING A MORE SUSTAINABLE INHALER

With growing pressure to tackle climate change, Phil Seeney looks at the arguments in favour of creating more sustainable inhalers, and examines potential strategies to accomplish it.

RESPIRATORY

Dr Robert Price

Nanopharm

DEVELOPING AN IN VITRO DISSOLUTION AND RELEASE SYSTEM FOR ORALLY INHALED DRUG PRODUCTS

Robert Price critiques regulatory routes for the development of generic OINDPs, runs through recent announcements and developments of note from regulators, and describes how Nanopharma has pioneered the concept of structural Q3 equivalence.

PHARMA VIEW

Dr Sara Panigone

Chiesi

ASTHMA & COPD: ENVIRONMENTAL SUSTAINABILITY & PATIENT-CENTRICITY

Sara Panigone, Federica Sandri and Gabriele Nicolini provide a considered and well-referenced analysis of carbon-minimal pMDIs for asthma and COPD, stressing the importance of balancing environmental sustainability with therapeutic efficacy to provide a sustainable and patient-centred solution.